Company Overview and News


Add MKGAF
to your dashboard

Headline News

German watchdog calls for direct comparison of cancer immunotherapies - Channel NewsAsia

2018-01-15 channelnewsasia
FRANKFURT: Germany's drug assessment body has criticized a lack of data directly comparing drugs in a promising new class of cancer immunotherapy, saying physicians could be overwhelmed or misled by the available information.

German watchdog calls for direct comparison of cancer immunotherapies

2018-01-15 reuters
FRANKFURT, Jan 15 (Reuters) - Germany’s drug assessment body has criticised a lack of data directly comparing drugs in a promising new class of cancer immunotherapy, saying physicians could be overwhelmed or misled by the available information.

Checkpoint Inhibitors Are Hot, and CKPT Has Something in the Oven

2018-01-11 finance.yahoo
NASDAQ:CKPT Checkpoint Therapeutics Inc. ( CKPT) holds a portfolio of targeted anti-cancer and immuno-oncology agents which it is developing for both mono- and combination therapies in solid tumors.  The company currently has six cancer compounds in preclinical and clinical stage development that focus on specific cellular markers and cancer signaling pathways.   In a previous article, we discussed the company’s third generation EGFR inhibitor, CK-101, including the drug’s significant potential market opportunity as a single-agent therapy for non-small cell lung cancer patients, as well as how it may realize synergies in combination with CK-301, an anti-PD-L1 checkpoint inhibitor antibody also under development by the company. (1-0)

Nestle frontrunner for Merck KGaA's consumer health business - Bloomberg

2018-01-10 reuters
ZURICH (Reuters) - Nestle (NESN.S) is the frontrunner to buy Merck KGaA’s (MRCG.DE) consumer health unit that could fetch as much as $5 billion, financial news service Bloomberg said on Wednesday, quoting unidentified sources familiar with the matter.

Fresenius CFO backs acquisition course -Boersen-Zeitung

2018-01-07 reuters
FRANKFURT (Reuters) - German healthcare group Fresenius (FREG.DE) will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company’s finance chief as saying. (19-0)

Claire's says lab results rebut Asbestos claims

2018-01-04 cnbc
Jewelry store Claire's said Thursday that lab results certified its products as asbestos-free, following allegations of the toxic substance in its products last month.

Hold On To Pfizer In 2018

2017-12-29 seekingalpha
Pfizer expects robust revenue growth for its biosimilars  as well as emerging markets portfolio in 2017. (14-0)

When To Sell A Stock (Even One You May Love)

2017-12-26 seekingalpha
If I look back at my investing mistakes (and I've made several), it's clear that I have more regrets about selling stocks than buying them. That's why I keep a portfolio of 40 dividend growth stocks that I never plan to sell. It gives me a way to remove my emotions from my investments and, maybe, if I'm lucky, to hold on to something special. (46-0)

Pharma Stock Roundup: Aerie's Rhopressa Approved, Label Expansion for BMY, Pfizer Drugs

2017-12-22 zacks
Key announcements this week include the FDA approval of an eye disease drug as well as a diabetes treatment and label expansions for existing products. Regulatory and pipeline updates were also provided by companies like AstraZeneca (AZN - Free Report) and Johnson & Johnson (JNJ - Free Report) . Recap of the Week’s Most Important Stories Aerie’s Rhopressa Gains FDA Approval: Aerie Pharmaceuticals (AERI - Free Report) got a boost with the earlier-than-expected FDA approval of Rhopressa for the lowering of elevated intraocular pressure (“IOP”) in patients with open-angle glaucoma or ocular hypertension. (162-0)

What's Happening in Advanced Renal Cell Carcinoma Space?

2017-12-21 zacks
The recent FDA approval of Exelixis, Inc.’s (EXEL - Free Report) Cabometyx for the treatment previously untreated advanced renal cell carcinoma has put the spotlight in this space. (56-1)

Your Daily Pharma Scoop: Valeant Still Risky, Onconova Signs Agreement, Array Biopharma Announces Collaboration

2017-12-20 seekingalpha
Today we will discuss an article on Valeant (VRX) by Michael Wiggins De Oliveira, titled, “Valeant: I Was Serious – The Clock Is Ticking.” (334-4)

Perrigo preparing non-binding bid for Merck KgaA's consumer health unit -sources

2017-12-14 reuters
LONDON/FRANKFURT (Reuters) - U.S. drugmaker Perrigo (PRGO.N) has decided to enter the fray for Merck KgaA’s (MRCG.DE) consumer health unit, sources told Reuters on Thursday, and is preparing an indicative offer for the $4.7 billion business ahead of the Dec. 15 deadline.

Germany's Merck to make new bid to enter U.S. MS pill market

2017-12-14 reuters
FRANKFURT (Reuters) - Germany’s Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales, after regulators’ concerns about side effects scuttled its ambitions almost seven years ago.

Verastem: Revisiting This Small Biotech Name After ASH

2017-12-13 seekingalpha
Verastem is analyzed after its presentation at the.American Society of Hematology conference in Atlanta this week. (41-0)

Nestle to buy supplements maker Atrium for $2.3 billion

2017-12-06 livemint
Geneva: Nestle SA chief executive officer Mark Schneider made his biggest acquisition yet, agreeing to buy Canadian dietary supplements maker Atrium Innovations for $2.3 billion in a bid for growth beyond stagnating mainstream food brands. (24-0)

CUSIP: 589339100